menu
    • menu

    Company profile for Onxeo

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Onxeo is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Our approach is based upon a unique mechanism of action of decoy agonist interfering with DNA Damage Response. We focus on bringing first-in-class and disruptive compounds from translational research to proof-of-concept in man in cancer indications with high unmet needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OnxeoFrance Flag
    Country
    Country
    France
    Address
    Address
    49, avenue du Général Martial Valin 75015 PARIS
    Telephone
    Telephone
    +33 (0) 1 45 58 76 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.onxeo.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/onxeo-onco/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer
    Onxeo Appoints Dr. Shefali Agarwal as President and Chief Executive Officer

    06 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220406006012/en

    BUSINESSWIRE
    06 Apr 2022
    Share Share
    Onxeo Further strengthens its Board of Directors two Seasoned Personalities
    Onxeo Further strengthens its Board of Directors two Seasoned Personalities

    14 Oct 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/10/14/2314652/0/en/Onxeo-Further-strengthens-its-Board-of-Directors-with-two-Seasoned-Personalities-from-the-Healthcare-Sector.html

    GLOBENEWSWIRE
    14 Oct 2021
    Share Share
    Onxeo Appointment of Dr. Shefali Agarwal as the Company Chairwoman of the Board
    Onxeo Appointment of Dr. Shefali Agarwal as the Company Chairwoman of the Board

    29 Jul 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/07/29/2271586/0/en/Onxeo-Announces-the-Appointment-of-Dr-Shefali-Agarwal-as-the-Company-s-Chairwoman-of-the-Board.html

    GLOBENEWSWIRE
    29 Jul 2021
    Share Share
    Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study
    Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study

    09 Nov 2020

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2020/11/09/2123061/0/en/Onxeo-Announces-Completion-of-Patient-Enrollment-in-DRIIV-1b-Study-and-Positive-Interim-Results.html

    GLOBENEWSWIRE
    09 Nov 2020
    Share Share
    ONXEO RECEIVES NOTICE OF INTENT TO GRANT A NEW PATENT ENHANCING
    ONXEO RECEIVES NOTICE OF INTENT TO GRANT A NEW PATENT ENHANCING

    23 Oct 2020

    // PRESS RELEASE

    https://www.onxeo.com/onxeo-receives-notice-of-intent-to-grant-a-new-patent-enhancing-the-protection-in-europe-of-asidna-combined-with-parp-inhibitors/#:~:text=10%2F22%2F2020-,Onxeo%20Receives%20Notice%20of%20Intent%20to%20Grant%20a%20New%20Patent,%E2%84%A2%20Combined%20with%20PARP%20Inhibitors&text=This%20patent%20will%20provide%20a,compounds%2C%20alone%20or%20in%20combination.

    PRESS RELEASE
    23 Oct 2020
    Share Share
    ONXEO ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE IB/II STUDY REVOCAN
    ONXEO ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE IB/II STUDY REVOCAN

    21 Oct 2020

    // PRESS RELEASE

    https://www.onxeo.com/onxeo-announces-enrollment-of-first-patient-in-phase-ib-ii-study-revocan/#:~:text=Onxeo%20Announces%20Enrollment%20of%20First%20Patient%20in%20Phase%20Ib%2FII%20Study%20Revocan,-Revocan%20is%20designed&text=Paris%20(France)%2C%20October%2021,7%20pm%20CEST%20%2D%20Onxeo%20S.A.&text=Acquired%20resistance%20to%20targeted%20therapies,develop%20such%20a%20resistance3.

    PRESS RELEASE
    21 Oct 2020
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search